For rare disease brands, launch readiness begins well before a therapy reaches the market. Approval is a critical milestone, but commercial success also depends on whether the right patients have been identified, physicians are prepared to recognize and manage the disease, referral and treatment pathways are taking shape, and the organization understands where gaps remain.
Those challenges are particularly pronounced in rare disease. Patient populations tend to be small and geographically dispersed, diagnosis can take years, and disease familiarity may be concentrated among a relatively narrow group of specialists. Patients may have moved through multiple physicians without receiving an accurate diagnosis or may have disengaged from the healthcare system altogether. For emerging biopharma companies preparing for an early or first launch, there may also be limited commercial infrastructure and few historical benchmarks to guide decisions.
All of this makes the period before approval commercially important. Disease education, patient-finding initiatives, symptom recognition, HCP education and advocacy engagement can help companies better understand the market they are preparing to enter while also supporting the patients, caregivers and physicians navigating it. Paid media can play an important role in that work when it is connected to the broader launch strategy and measured with the same discipline that will eventually be applied to commercial activity.
The measurement piece is especially important. Traditional media metrics such as impressions, clicks, reach and frequency provide useful information about delivery and engagement, but they offer only a partial view of readiness. In rare disease, marketers should also be looking for signs that education and engagement are contributing to movement through the patient and physician journey. That might include engagement with symptom or diagnostic information, specialist-finder use, testing inquiries, referrals, HCP interaction with disease education, or activity across patient advocacy and registry programs.
Over time, those signals can help marketers understand whether the diagnosed and potentially eligible patient population is growing, whether the appropriate physicians are becoming more active and whether care pathways are developing ahead of launch. This requires measurement to be established early. Claims, genetic or biomarker testing, EHR or EMR data, NPI-level HCP activity, website and search behavior, CRM information and advocacy data can each provide a different view of how the market is evolving. Looking across several of these sources gives commercial teams a more useful picture than relying on campaign performance alone.
There also needs to be discipline around what those signals can prove. Media operates alongside clinical evidence, access, pricing, patient services, advocacy, field activity and many other factors that influence a launch. Establishing baselines, using matched cohorts or control markets where appropriate, and connecting exposure to downstream activity can help companies understand media’s contribution without overstating causality. The objective is to build enough evidence over time to know where the market is moving and where additional investment or attention may be needed.
This approach ultimately gives marketing teams a more meaningful way to discuss pre-launch investment with commercial leadership. Instead of limiting the conversation to how many people were reached or how efficiently media was delivered, teams can examine whether patient finding is improving, whether physicians are becoming more prepared, whether referral pathways are developing and whether the launch-ready population is expanding.
For rare disease companies, those are questions worth answering before approval. The months leading into launch provide an opportunity to identify gaps while there is still time to address them, build evidence around what is working and enter the market with a clearer understanding of the patients, physicians and pathways that will ultimately determine uptake. Pre-launch media earns its place in that process when it helps the organization build a market that is prepared to move.